RecruitingPhase 2Phase 3NCT06423729

Effect of Nicorandil in Type 2 Diabetic Obese Patients

Clinical Study Evaluating the Effect of Nicorandil in Type 2 Diabetic Obese Patients Treated With Sulfonylurea


Sponsor

Tanta University

Enrollment

46 participants

Start Date

Jun 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

1. Evaluating the effect of nicorandil on glycemic control of diabetic obese patients treated with sulfonylureas. 2. Investigating the effect of nicorandil on body weight of diabetic obese patients treated with sulfonylureas.


Eligibility

Min Age: 18 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This study is examining the effects of nicorandil — a drug usually used for chest pain — in people with Type 2 diabetes who are also obese. The goal is to see whether nicorandil has additional benefits for blood sugar control or other health measures in this population. **You may be eligible if...** - You are between 18 and 60 years old - You have had Type 2 diabetes for 1–10 years - Your BMI is above 30 (classified as obese) - You are currently being treated with sulfonylurea medication only (a common diabetes pill) **You may NOT be eligible if...** - You are pregnant or breastfeeding - You are allergic to nicorandil - You have uncontrolled high blood pressure - You have severe kidney or liver disease Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNicorandil 10 MG

Patients will receive oral Nicorandil 10 MG twice daily in addition to 2nd generation sulfonylureas , for 3 months.


Locations(1)

Faculty of Pharmacy, Tanta University

Tanta, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06423729


Related Trials